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Primary sclerosing cholangitis (PSC) is the rare chronic liver disease par excellence for 
which clinicians and patients alike seek better treatments; principally interventions that 
reduce the need for liver transplantation and that materially change the devastating natural 
history of symptomatic cholangitis, end-stage liver failure and unpredictable malignancy.  
This goal is complicated by a complex, heterogeneous etiopathogenesis and clinical course, 
characterised by facets of disease that are autoimmune, cholestatic, inflammatory, pro-
fibrotic, pre-malignant and associated with inflammatory bowel disease (1) (2). PSC is 
symptomatic in the majority and above all for individuals living with this disease provokes 
anxiety in patients, family and carers.  When asked, patients will readily volunteer the impact 
of pain, itch, fatigue, and uncertainty (3) (4). One online survey run by PSC Support 
(www.pscsupport.org.uk) involving over 1000 respondents found that the most difficult thing 
for patients about living with PSC was the impact on their emotional well-being (cited by 
74% of respondents), with specific concerns including uncertainty about the future, 
helplessness and concern about their medical care and monitoring. 
 
In parallel to the pursuit of therapies that slow down the inflammatory and pro-fibrotic 
pathways associated with a relentless cholangiocyte injury, there is a paramount need for 
improvement to outcomes that therefore equally address an individual’s quality of life, as 
well as quantity (Figure 1).  In what is a difficult clinical trials arena, discussions continue 
about what is an appropriate efficacy end-point at different stages of a product’s development 
(5). One key consensus has been the need for future trial opportunities to place greater 
emphasis on patient reported outcomes that include, in particular, the participant’s quality of 
life.  At the present time, dedicated tools that can reproducibly measure such an important 
vector within disease trajectory are not available consistently and certainly are not PSC 
specific. Patient reported outcome measures (PROMs) assess not only physical symptoms, 
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but also mental and social well-being, overall providing data as to the real impact of disease 
on patients’ everyday lives. Disease-specific PROMs are felt to be more informative in 
delineating domains more specific to one particular disease, allowing for more patient-
centred assessment.  
 
In this issue of Hepatology, Younossi et al. describe the development of a new PSC-specific 
PROM instrument (6). This work, an important partner to a trial programme, is worthy of 
comment, because albeit not complete, it marks a transition point for the community. The 
instrument was initially developed using qualitative interviewing of participants with PSC; a 
draft was drawn up after the first 20 interviews and it was then validated by a further 26 
independent participant interviews. While small numbers, this is standard practice for 
qualitative research methodology, where the number of interviews is often aimed at around 
15-25; for a disease heterogeneous in its very core, validation of this approach will however 
be important in PSC. Once relevant changes had been made to the PROM instrument 
throughout, the final design contained 42 questions divided into two modules; the first 
describes symptom severity whereas the second describes the impact of the disease. The 
“impact of disease” module includes domains such as physical function, work productivity, 
role function, emotional impact and quality of life. The finalised PROM was then validated in 
102 external participants with PSC along with 4 other commonly used PROM instruments: 
SF-36, CLDQ, PBC-40 and 5D-itch. 53 participants with PSC who were assessed as 
clinically stable then repeated the instrument again within three months to assess for 
consistency.  
 
Globally the authors report patient satisfaction with the instrument and consistency was found 
with repeated measurements, in the scenario of clinical stability. There was a skewed 
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distribution of domain scores towards the lower values, suggesting better health status or 
possibly due to a “floor” effect. Significant correlations were seen with the other PROM 
instruments; this correlation was seen less with the 5D-Itch scale and the authors reported that 
no correlation was more than 90%, indicating the role for a PSC-specific instrument.  
 
This study equally illustrates limitations and challenges in this area. The population evaluated 
is clearly small and the repeated measurements were completed in short succession. One-
third of the external validation cohort was male, with considerably higher scores in multiple 
domains. This is rather a lower sex ratio than is traditionally recognised for PSC, and thus the 
application of the tool in the wider PSC population is going to be important.  How the tool 
will fare in diverse settings with varying participant background will be a key aspect of its 
development. It is also unclear what effect ‘survey fatigue’ may have had on patients who 
were completing five separate instruments concurrently or how feasible a 7-15 minute 
instrument may be in differing clinical settings. A further limitation raised by the authors is 
that the role of co-morbid inflammatory bowel disease (IBD) could not be de-lineated via this 
instrument, meaning an IBD-specific PROM is also required. This is significant as there is 
established evidence as to IBD being a major determinant of quality of life in PSC, and given 
the close association between diseases and potential therapies, accurate recognition of the 
role of concomitant IBD in a participant’s quality of life is important.   
 
Beyond drug therapy, it is also likely that “how” we care for patients has important impacts 
on their experiences, in addition to disease-specific medical management itself.  Within the 
management of this complex rare disease and its impact upon patients, must equally be 
layered the structural/logistic health care delivery issues that vary globally; these issues are 
also contributors (and opportunities) to ultimate patient experience and overall quality of life.  
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It is also worth considering how use of disease-specific PROM tools could be used to 
improve routine care for patients e.g. serial monitoring of PROM tool outputs for a patient 
could be used to trigger clinical review and investigations in a more targeted response-driven 
approach to care.  
 
Whilst acknowledged by the authors that this PROM instrument needs further validation in a 
larger, multi-national cohort and with further assessment of the sensitivity of the instrument 
to clinical changes over time, the study and its outcomes are nevertheless a step forward. 
Once a validated disease-specific PROM instrument is embedded into practice we reach one 
step further towards obtaining varied clinically meaningful endpoints for PSC, by being able 
to design clinical trials tailored to produce measurable whole patient benefit. This is a 
complex area and difficulties remain as to how to delineate quality of life impact that is liver-
specific, bowel-specific, or indeed PSC-IBD specific.  Data from PROMs will form part of a 
regulators assessment of a new therapy but will always be just one aspect of evaluable data: 
the new therapy for primary biliary cholangitis (PBC), obeticholic acid, is the first new 
licenced opportunity for patients with PBC, yet it’s close biologic properties have both 
positive disease impact, as well as potential deleterious symptom side-effects.  For future 
therapies in PSC similar challenges may also arise. Not with-standing these challenges 
encountered by patients with PSC, there is renewed optimism that the intensity of effort being 
afforded to the many spinning tops PSC presents, across many domains of health, is 
increasingly being recognised as progress. 
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Figure legend 
 
Figure 1:  Priorities in care for patients with primary sclerosing cholangitis: an entangled 
lattice of unpredictability and anxiety.  
 
For patients with PSC, disease associated complications, co-morbidities, the need for access 
to specialist medical management and the development of new therapies, compete in 
significance to a ‘crisis’ faced by the unpredictable nature of PSC and the resulting effects on 
an individual’s personal narrative, social status and economic potential. Therapies and 
clinical care pathways that derive overall benefit to the many faceted domains of relevance to 
patients will prove more successful and durable. 
 
  
 
 
 8 
References 
 
1. Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. 
Lancet. 2013;382(9904):1587-99. 
2. Arndtz K, Hirschfield GM. Primary sclerosing cholangitis and the management of 
uncertainty and complexity. Frontline gastroenterology. 2017;8(4):260-6. 
3. Cheung AC, Patel H, Meza-Cardona J, Cino M, Sockalingam S, Hirschfield GM. Factors 
that Influence Health-Related Quality of Life in Patients with Primary Sclerosing Cholangitis. 
Digestive diseases and sciences. 2016;61(6):1692-9. 
4. Haapamaki J, Tenca A, Sintonen H, Barner-Rasmussen N, Farkkila MA. Health-related 
quality of life among patients with primary sclerosing cholangitis. Liver international. 
2015;35(9):2194-201. 
5. Ponsioen CY, Chapman RW, Chazouilleres O, Hirschfield GM, Karlsen TH, Lohse AW, 
et al. Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and 
results from an International PSC Study Group consensus process. Hepatology. 
2016;63(4):1357-67. 
6. Younossi ZM, Afendy A, Stepanova M, Racila A, Nader F, Gomel R, et al. 
Development and Validation of a Primary Sclerosing Cholangitis-Specific Patient-Reported 
Outcomes Instrument: The PSC PRO. Hepatology 2017 Nov 20 doi: 101002/hep29664. 2017. 
 
